Search Results - "Romaguera, J."

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes by Cheah, C.Y., Chihara, D., Romaguera, J.E., Fowler, N.H., Seymour, J.F., Hagemeister, F.B., Champlin, R.E., Wang, M.L.

“…Although ibrutinib is highly effective in patients with relapsed/refractory mantle cell lymphoma (MCL), a substantial proportion of patients have resistant…”
Get full text

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial by Wang, M, Fowler, N, Wagner-Bartak, N, Feng, L, Romaguera, J, Neelapu, S S, Hagemeister, F, Fanale, M, Oki, Y, Pro, B, Shah, J, Thomas, S, Younes, A, Hosing, C, Zhang, L, Newberry, K J, Desai, M, Cheng, N, Badillo, M, Bejarano, M, Chen, Y, Young, K H, Champlin, R, Kwak, L, Fayad, L

“…Lenalidomide–rituximab therapy is effective in grade 1–2 follicular and mantle cell lymphoma, but its efficacy in diffuse large B-cell lymphoma (DLBCL),…”
Get full text

A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome by Vadhan-Raj, S., Fayad, L.E., Fanale, M.A., Pro, B., Rodriguez, A., Hagemeister, F.B., Bueso-Ramos, C.E., Zhou, X., McLaughlin, P.W., Fowler, N., Shah, J., Orlowski, R.Z., Samaniego, F., Wang, M., Cortes, J.E., Younes, A., Kwak, L.W., Sarlis, N.J., Romaguera, J.E.

“…Tumor lysis syndrome (TLS) is a life-threatening disorder characterized by hyperuricemia and metabolic derangements. The efficacy of rasburicase, administered…”
Get full text

Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes by Cheah, C.Y., Chihara, D., Horowitz, S., Sevin, A., Oki, Y., Zhou, S., Fowler, N.H., Romaguera, J.E., Turturro, F., Hagemeister, F.B., Fayad, L.E., Wang, M., Neelapu, S.S., Nastoupil, L.J., Westin, J.R., Rodriguez, M.A., Samaniego, F., Anderlini, P., Nieto, Y., Fanale, M.A.

“…Brentuximab vedotin (BV) is a key therapeutic agent for patients with relapsed/refractory classical Hodgkin lymphoma (cHL). The outcomes of patients…”
Get full text

Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era by Cheah, C.Y., Chihara, D., Ahmed, M., Davis, R.E., Nastoupil, L.J., Phansalkar, K., Hagemeister, F.B., Fayad, L.E., Westin, J.R., Oki, Y., Fanale, M.A., Romaguera, J.E., Wang, M.L., Lee, H., Turturro, F., Samaniego, F., Rodriguez, M.A., Neelapu, S.S., Fowler, N.H.

“…The optimal initial therapy of follicular lymphoma (FL) remains unclear. The aims of this study were to compare primary treatment strategies and assess the…”
Get full text

Targeting the reconsolidation of extinction memories: a novel potential strategy to treat anxiety disorders by Rosas-Vidal, L E, Rodriguez-Romaguera, J, Do-Monte, F H, Andero, R

Get full text

Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma by Esmaeli, B., McLaughlin, P., Pro, B., Samaniego, F., Gayed, I., Hagemeister, F., Romaguera, J., Cabanillas, F., Neelapu, S. S., Banay, R., Fayad, L., Wayne Saville, M., Kwak, L. W.

“…Background: To determine the efficacy and side-effects of 90Y ibritumomab tiuxetan (Zevalin) as front-line treatment in patients with early-stage extranodal…”
Get full text

Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo by Wang, M, Han, X H, Zhang, L, Yang, J, Qian, J F, Shi, Y K, Kwak, L W, Romaguera, J, Yi, Q

“…Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma with poor clinical outcome. Although front therapy induces a high rate of complete remission (CR),…”
Get full text

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience by Anderlini, Paolo, Saliba, Rima, Acholonu, Sandra, Giralt, Sergio A, Andersson, Borje, Ueno, Naoto T, Hosing, Chitra, Khouri, Issa F, Couriel, Daniel, de Lima, Marcos, Qazilbash, Muzaffar H, Pro, Barbara, Romaguera, Jorge, Fayad, Luis, Hagemeister, Frederick, Younes, Anas, Munsell, Mark F, Champlin, Richard E

“…1 Department of Stem Cell Transplantation and Cellular Therapy; 2 Lymphoma and 3 Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston,…”
Get full text

Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma by McLaughlin, P, Hagemeister, F B, Romaguera, J E, Sarris, A H, Pate, O, Younes, A, Swan, F, Keating, M, Cabanillas, F

“…Although most patients with indolent lymphomas respond to initial therapy, virtually all experience relapse. Secondary therapy is often beneficial, but…”
Get more information

PROGNOSTIC VALUE OF PRE‐TREATMENT PET SCAN IN PATIENTS WITH FOLLICULAR LYMPHOMA RECEIVING FRONTLINE THERAPY by Strati, P., Ahmed, M., Fowler, N., Hagemeister, F., Fayad, L., Rodriguez, M., Samaniego, F., Wang, M., Westin, J.R., Romaguera, J., Noorani, M., Phansalkar, K., Cheah, C., Feng, L., Davis, R.E., Nastoupil, L., Neelapu, S.S.

Get full text

COMBINATION OF IBRUTINIB WITH RITUXIMAB (IR) IS HIGHLY EFFECTIVE IN PREVIOUSLY UNTREATED ELDERLY (>65 YEARS) PATIENTS (PTS) WITH MANTLE CELL LYMPHOMA (MCL) – PHASE II TRIAL by Jain, P., Romaguera, J., Nomie, K., Zhang, S., Wang, L., Oriabure, O., Wagner‐Bartak, N., Zhang, L., Hagemeister, F., Samaniego, F., Westin, J., Ju Lee, H., Nastoupil, L., Iyer, S., Parmar, S., Ok, C., Kanagal‐Shamanna, R., Chen, W., Thirumurthi, S., Santos, D., Badillo, M., Fayad, L., Neelapu, S., Fowler, N., Wang, M.

Get full text

COMPREHENSIVE ANALYSIS OF PROGNOSTIC FACTORS, OUTCOMES AND MUTATION PROFILE IN PATIENTS WITH AGGRESSIVE HISTOLOGY (BLASTOID/PLEOMORPHIC) OR TRANSFORMED MANTLE CELL LYMPHOMA by Jain, P., Kanagal‐Shamanna, R., Zhang, S., Ok, C., Nogueras Gonzalez, G., Gonzalez‐Pagan, O., Ghorab, A., Boddu, P., Chen, W., Lee, H. Ju, Nomie, K., Fayad, L., Westin, J., Nastoupil, L., Patel, K., Ahmed, S., Iyer, S.P., Parmar, S., Champlin, R., Neelapu, S., Medeiros, J.L., Romaguera, J., Fowler, N., Wang, L., Wang, M.L.

Get full text

IBRUTINIB WITH RITUXIMAB (IR) AND SHORT COURSE R‐HYPERCVAD/MTX IS VERY EFFICACIOUS IN PREVIOUSLY UNTREATED YOUNG PTS WITH MANTLE CELL LYMPHOMA (MCL) by Wang, M., Jain, P., Zhang, S., Nomie, K., Wang, L., Oriabure, O., Nogueras Gonzales, G., Zhang, L., Wagner‐Bartak, N., Hagemeister, F., Samaniego, F., Westin, J., Lee, H.J., Nastoupil, L., Ok, C., Kanagal‐Shamanna, R., Chen, W., Thirumurthi, S., Santos, D., Badillo, M., Fayad, L., Neelapu, S., Fowler, N., Romaguera, J.

Get full text

Radiation Therapy Is a Very Effective Modality in the Treatment of Mantle Cell Lymphoma, >80% Complete Disappearance of Disease Site in Heavily Pretreated Patients by Dabaja, B, Voong, R, Shihadeh, F, Arzu, I, Pinnix, C, Mazloom, A, Medeiros, L, Romaguera, J, Rodriguez, M, Allen, P

Get full text

Improved outcome for patients with relapsed/refractory mantle cell lymphoma (MCL) who stop ibrutinib +/− rituximab for reasons other than progression of disease by Chen, W., Zeng, D., Desai, A., Badillo, M., Feng, L., Yan, F., Nomie, K., Ping, L., Ye, H., Liang, Y., Lee, H., Oki, Y., Romaguera, J., Wang, M.

Get full text

The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma by Overman, M.J., Feng, L., Pro, B., McLaughlin, P., Hess, M., Samaniego, F., Younes, A., Romaguera, J.E., Hagemeister, F.B., Kwak, L., Cabanillas, F., Rodriguez, M.A., Fayad, L.E.

“…The benefit of adding rituximab to anthracycline-based therapy for follicular lymphoma grade 3 has not been studied. We retrospectively reviewed the records of…”
Get full text

Antibiotic treatment of Gastric lymphoma of mucosa-associated lymphoid tissue : An uncontrolled trial by STEINBACH, G, FORD, R, YOUNES, A, LUTHRA, R, MANNING, J. T, JOHNSON, C. M, LAHOTI, S, YUSHEN, LEE, J. E, WINN, R. J, GENTA, R. M, GRAHAM, D. Y, GLOBER, G, CABANILLAS, F. F, SAMPLE, D, HAGEMEISTER, F. B, LYNCH, P. M, MCLAUGHLIN, P. W, RODRIGUEZ, M. A, ROMAGUERA, J. E, SARRIS, A. H

“…Gastric lymphoma of mucosa-associated lymphoid tissue (MALT) is related to Helicobacter pylori infection and may depend on this infection for growth. To…”
Get full text

Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen by ANDERLINI, P, SALIBA, R, HOSING, C, COHEN, A, IPPOLITI, C, ROMAGUERA, J, RODRIGUEZ, M. A, PRO, B, FAYAD, L, GOY, A, YOUNES, A, CHAMPLIN, R. E, ACHOLONU, S, OKOROJI, G.-J, DONATO, M, GIRALT, S, ANDERSSON, B, UENO, N. T, KHOURI, I, DE LIMA, M

“…A total of 40 patients with relapsed/refractory Hodgkin's disease (HD) underwent reduced-intensity conditioning (RIC) allogeneic stem cell transplantation…”
Get full text

Factors Associated with HPV Vaccine Awareness in a Population-Based Sample of Hispanic Women in Puerto Rico by Romaguera, J., Caballero-Varona, D., Tortolero-Luna, G., Marrero, E., Suárez, E., Pérez, C. M., Muñoz, C., Palefsky, J., Ortiz, A. P.

“…Objectives The objective of this study was to investigate the factors associated with HPV awareness among women aged 16 to 64 years, among underserved minority…”
Get full text